Capricor Therapeutics
CAPR
14 hedge funds and large institutions have $2.9M invested in Capricor Therapeutics in 2015 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 7 → 14 (+7)
46% less capital invested
Capital invested by funds: $5.36M → $2.9M (-$2.46M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.62M |
| 2 |
Goldman Sachs
New York
|
+$403K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$276K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$84.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$76.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$3.69M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.33K |
CAPR Hedge Fund Activity: Q2 2015 in Review
14 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q2 2015, worth a combined $2.9M — down 46% from $5.36M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CAPR positions and 0 closed out — a net gain of 7 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.62M. The largest seller was Broadfin Capital, cutting an estimated $3.69M.
- 14 institutional investors held Capricor Therapeutics (CAPR) as of Q2 2015, up from 7 in Q1 2015.
- Funds reported $2.9M of Capricor Therapeutics stock for Q2 2015, down 46% quarter-over-quarter.
- 7 funds opened new Capricor Therapeutics positions in Q2 2015 and 0 closed out, a net change of +7 holders.
- The largest Capricor Therapeutics buyer in Q2 2015 was Sabby Management, an estimated $1.62M added.
- The largest Capricor Therapeutics seller in Q2 2015 was Broadfin Capital, an estimated $3.69M sold.
Based on aggregated 13F filings for Q2 2015.